Evidence map›Paper›PMID 39149401›Full record

ArticlebioRxiv : the preprint server for biology2024

Machine learning enables high-throughput, low-replicate screening for novel anti-seizure targets and compounds using combined movement and calcium fluorescence in larval zebrafish.

Christopher Michael McGraw, Annapurna Poduri

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Christopher Michael McGrawDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-5460-4550
Annapurna PoduriDepartment of Neurology, The F.M. Kirby Neurobiology Center, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-7350-5136

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI Hisashi Umemori · 2021 to 2026
$9.4M
Developing a Zebrafish Model of Slc6a1/GAT1 Hypofunction and an In Vitro Assay to Identify Novel TreatmentsK08NS118107 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI MCGRAW, CHRISTOPHER · 2020 to 2024
$1.1M
NICHD NIH HHS P50 HD105351NINDS NIH HHS K08 NS118107
6 · The paper itself

Abstract

Identifying new, more efficacious anti-seizure medications (ASMs) is challenging, partly due to limitations in animal-based assays. Zebrafish (

Indexed as

calcium fluorescencehigh-throughput imagingpro-convulsantsPTZSeizureszebrafish

Identifiers

PMID39149401
PMCPMC11326203

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.